Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Janisch

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
American Journal of Clinical Oncology|June 17, 2000
A phase I study of liposomal doxorubicin (Doxil) with topotecanC W Ryan, G F Fleming, L Janisch, et al.
Cancer|April 1, 1993
A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2aM J Ratain, E R Priest, L Janisch, et al.
Cancer|June 1, 1996
Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor supportG F Fleming, L Janisch, N J Vogelzang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1996
Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated doseK Kobayashi, E E Vokes, N J Vogelzang, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesisG F Fleming, E E Vokes, J M McEvilly, et al.
Cancer Research|March 15, 1993
Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancerR L Schilsky, L Janisch, F Berezin, et al.
Cancer Research|January 1, 1994
Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456)N J Vogelzang, R Mick, L Janisch, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignanciesR A Larson, R B Geller, L Janisch, et al.
Cancer|December 1, 1996
Mineralocorticoid insufficiency due to suramin therapyK Kobayashi, R E Weiss, N J Vogelzang, et al.
Oncology Reports|May 25, 2011
Phase-I trial of Thiotepa, granulocyte-macrophage colony-stimulating factor and prednisone or pentoxifylline in patients with refractory solid tumorsS Devine, M Ratain, L Janisch, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
American Journal of Clinical Oncology|June 17, 2000
A phase I study of liposomal doxorubicin (Doxil) with topotecanC W Ryan, G F Fleming, L Janisch, et al.
Cancer|April 1, 1993
A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2aM J Ratain, E R Priest, L Janisch, et al.
Cancer|June 1, 1996
Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor supportG F Fleming, L Janisch, N J Vogelzang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1996
Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated doseK Kobayashi, E E Vokes, N J Vogelzang, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesisG F Fleming, E E Vokes, J M McEvilly, et al.
Cancer Research|March 15, 1993
Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancerR L Schilsky, L Janisch, F Berezin, et al.
Cancer Research|January 1, 1994
Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456)N J Vogelzang, R Mick, L Janisch, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignanciesR A Larson, R B Geller, L Janisch, et al.
Cancer|December 1, 1996
Mineralocorticoid insufficiency due to suramin therapyK Kobayashi, R E Weiss, N J Vogelzang, et al.
Oncology Reports|May 25, 2011
Phase-I trial of Thiotepa, granulocyte-macrophage colony-stimulating factor and prednisone or pentoxifylline in patients with refractory solid tumorsS Devine, M Ratain, L Janisch, et al.
Pageof 3